Purity >95%. CC-115 is a potent dual inhibitor of mTOR and DNA-PK (IC50 s = 22 and 15 nM, respectively). CC-115 reduces PC3 cancer cell growth in vitro (IC50 = 138 nM) and exhibits effective reduction of murine PC3 tumor xenografts (mEC50 = 1 mg/kg). In a Phase I clinical trial, formulations containing CC-115 reduced lymph node sizes in almost all patients with chronic lymphocytic leukemia (CLL) that also have ataxia telangiectasia mutated (ATM) kinase deletions.